Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 11Active not recruiting 7Terminated 6Recruiting 4Withdrawn 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Liver Neoplasms 2Treatment-Refractory Solid Tumors 1Rare Tumour 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Extensive Stage Lung Small Cell Cancer 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 4trastuzumab deruxtecan 3fludarabine 3Standard of Care 3Injections 3Cisplatin 3Bevacizumab 3toripalimab 2sacituzumab govitecan 2pembrolizumab 2fludarabine phosphate 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Palliative Care 2Gemcitabine 2Fulvestrant 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2zimberelimab 1vedolizumab 1tislelizumab 1sintilimab 1lobaplatin 1lenvatinib 1ivosidenib 1irinotecan sucrosofate 1exemestane 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Neoplasm Metastasis × atezolizumab × Clear all
NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest Therapeutics

Phase 3 Not yet recruiting
740 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡